FDA Commissioner's India Trip Underscores Quality Theme and Regulatory Leverage
This article was originally published in RPM Report
Executive Summary
Hamburg goes to engage and educate but also to deliver a message to Indian manufacturers: FDA has more funding, human resources, and authorities than it has ever had before to regulate firms outside of the US.
You may also be interested in...
Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting
FDA has essentially shut down Ranbaxy’s three-year-old facility at Mohali as a source for products for the US market. But Ranbaxy is not alone among Indian firms in its quality product disputes with the agency. There is a significant uptick in activity by FDA in the region in what appears to be a period of intense culturization for the Indian firms into the ways FDA enforces cGMPs and handles on-site inspections.
FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
CMS remains open to the idea of using parallel review (or, less formal parallel advice) for prescription drugs, but the current and future focus of the pilot program is likely to stay on devices and diagnostics.
Personalized Medicine Meets Payment Policy: MEDCAC Has “Low Confidence” In Most Cancer Tests
Genomic screening of tumor types may be the cutting edge in cancer treatment and a central component of the President’s vision for personalized medicine. But how much evidence is necessary to make insurance coverage for testing routine?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: